LINDELL ANDREA R
Known title: DirectorCIK: 0001224643
Transaction History
| CHE | ▼ Sell | Open Market | 1,347 | $603K | 6/9/2026 | View on chart |
| CHE | ▲ Buy | Grant | 386 | $170K | 5/18/2026 | View on chart |
| CHE | ▼ Sell | Gift | 463 | $0 | 12/26/2025 | View on chart |
| CHE | ▲ Buy | Grant | 277 | $160K | 5/19/2025 | View on chart |
| CHE | ▼ Sell | Open Market | 831 | $475K | 8/16/2024 | View on chart |
| CHE | ▲ Buy | Grant | 284 | $160K | 5/20/2024 | View on chart |
| CHE | ▲ Buy | Grant | 294 | $160K | 5/15/2023 | View on chart |
| CHE | ▲ Buy | Grant | 262 | $130K | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Chemed to report Q3 2026 earnings on October 27
Chemed Corp is scheduled to release its third-quarter 2026 earnings on October 27, with a conference call following on October 28. This upcoming report is the primary focus for investors, as it will provide the latest financial results for the company. While the stock currently trades below its average analyst target price, the near-term attention remains on the details of this earnings announcement.
Chemed to report Q3 2026 earnings on October 27. Chemed Corp is scheduled to release its third-quarter 2026 earnings on October 27, with a conference call following on October 28. This upcoming report is the primary focus for investors, as it will provide the latest financial results for the company. While the stock currently trades below its average analyst target price, the near-term attention remains on the details of this earnings announcement.